{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:16Z","timestamp":1792123096004,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jaad.2020.08.137","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:25:49Z","timestamp":1607023549000},"page":"1310-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group"],"prefix":"10.1016","volume":"84","author":[{"given":"Vasiliki","family":"Nikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Sollena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Ortiz-Brugu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Giacchero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Voudouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilios","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Patri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.08.137_bib1","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O\u2019Reilly","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.08.137_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PDL1immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2020.08.137_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicity and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1- Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib7","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis. A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Banobre","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1078155219877234","article-title":"Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer","volume":"26","author":"Guven","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2020.08.137_bib11","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/1346-8138.14167","article-title":"New onset psoriasis during nivolumab treatment for lung cancer","volume":"45","author":"Chujo","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reaction by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review","volume":"10","author":"DeBock","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib14","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/ijd.14457","article-title":"Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer","volume":"58","author":"Scarfi","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.08.137_bib16","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris\u2014update 2015; Short version\u2014EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.137_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.137_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.08.137_bib20","first-page":"1","article-title":"Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer","volume":"24","author":"Aso","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.08.137_bib21","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.08.137_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunology cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ajd.12889","article-title":"Psoriasis and cancer. An Australian\/New Zealand narrative","volume":"60","author":"Rademaker","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.137_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.08.137_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5826\/dpc.0904a11","article-title":"Psoriasis in patients with active lung cancer: is apremilast a safe option?","volume":"9","author":"Apalla","year":"2019","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.jaad.2020.08.137_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2169\/internalmedicine.3694-19","article-title":"Systemic psoriasiform dermatitis appeared after the administration of pembrolizumab","volume":"59","author":"Suzuki","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.jaad.2020.08.137_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies","volume":"53","author":"Micic","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2020.08.137_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.15698\/cst2019.07.193","article-title":"Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity","volume":"3","author":"Alvarez","year":"2019","journal-title":"Cell Stress"},{"key":"10.1016\/j.jaad.2020.08.137_bib30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:51Z","timestamp":1759273131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220331157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0190962220331157"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.137","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739167063.793580981","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}